ArticleAmerican journal of clinical and experimental urology2018
NKX3.1 and PSMA are sensitive diagnostic markers for prostatic carcinoma in bone metastasis after decalcification of specimens.
Article in American journal of clinical and experimental urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience.The oncologist · 2021Trial
- Below-the-Radar: A Case of Extensive Osseous Metastasis of Prostate Cancer Confined Exclusively to One Lower Limb.Clinical nuclear medicine · 2025Article
- Molecular diagnostics of prostate cancer: impact of molecular tests.Asian journal of andrology · 2024Review
- NKX3.1 Expression Contributes to Epithelial-Mesenchymal Transition of Prostate Cancer Cells.ACS omega · 2023Article
- A gut-restricted glutamate carboxypeptidase II inhibitor reduces monocytic inflammation and improves preclinical colitis.Science translational medicine · 2023Article
- Novel Histopathological Biomarkers in Prostate Cancer: Implications and Perspectives.Biomedicines · 2023Review
- Tissue immunostaining of candidate prognostic proteins in metastatic and non-metastatic prostate cancer.Journal of cancer research and clinical oncology · 2023Article
- Validation of potential RNA biomarkers for prostate cancer diagnosis and monitoring in plasma and urinary extracellular vesicles.Frontiers in molecular biosciences · 2023Article
- Article
- NKX3-1 Is a Useful Immunohistochemical Marker of EWSR1-NFATC2 Sarcoma and Mesenchymal Chondrosarcoma.The American journal of surgical pathology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate specific antigen (PSA), prostate specific membrane antigen (PSMA), and NKX3.1 are sensitive and prostate-specific markers frequently used for the diagnosis of metastatic prostate cancer (mPCa). International Society of Urological Pathology recommends use of PSA as the initial immunohistochemical (IHC) marker to identify PCa. If the tumor is equivocal/weak/negative for PSA, then P501S and NKX3.1 stains are suggested. However, no specific studies have attempted to compare the staining sensitivity of these markers post specimen decalcification of bone specimens. In this study, we analyze the staining sensitivity of PSA, PSMA and NKX3.1 in bone specimens with mPCa after decalcification.
designWe studied 24 cases of mPCa to the bone. All cases were decalcified for 24 to 48 hours prior to H&E staining and IHC workup. Eight cases were biopsies from vertebral bodies, five were from the femur, four came from the iliac bone, two were from ribs, three were from the pubic ramus, one was from the sacrum and one was from the skull. IHC staining pattern of PSA, PSMA and NKX3.1 was defined as follows: negative (no staining), focally positive (≤ 10%) and diffusely positive (≥ 10%). Focal and diffuse positivity are both considered positive.
resultsPSA was positive in 64% (14/22) cases, while PSMA and NKX3.1 were positive in all cases (17/17 and 24/24, respectively). The frequency of positive PSMA staining in decalcified samples of prostatic carcinoma metastatic to the bone is statistically higher than that of PSA staining, when analyzed by the Chi-square test (Chi-square statistic: 5.389; P = 0.0203). The frequency of positive NKX3.1 staining in decalcified samples of prostatic carcinoma metastatic to the bone is also statistically higher than that of PSA staining, when analyzed by the Chi-square test (Chi-square statistic: 10.56; P = 0.0012). When comparing PSMA and NKX3.1 positive staining, NKX3.1 tended to be diffusely positive at a higher frequency. However, this difference was not statistically significant.
conclusionThis study demonstrates that PSMA and NKX3.1 are more sensitive markers than PSA for mPCa to the bone following decalcification. We recommend use of PSMA and NKX3.1, rather than PSA, as the IHC markers to confirm mPCa to the bone.
Indexed as
Identifiers
30510970PMC6261873W2991202971What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.